Collectively, these findings underscore the need for a comprehensive understanding of resistance mechanisms and the development of novel therapeutic strategies beyond ATP-competitive inhibition to achieve durable remission in FLT3-mutated AML. Here, FLT3 is linked to acute myeloid leukemia.